E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
EOSINOPHILIC ESOPHAGITIS |
ESOFAGITE EOSINOFILA |
|
E.1.1.1 | Medical condition in easily understood language |
Eosinophilic esophagitis (EoE) is a chronic disease that affects food intake and quality of life. |
L’esofagite eosinofila (Eosinophilic esophagitis, [EoE]) è una malattia cronica che influisce sull’assunzione di cibo e sulla qualità della vita. |
|
E.1.1.2 | Therapeutic area | Body processes [G] - Digestive System and Oral Physiological Phenomena [G10] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10064220 |
E.1.2 | Term | Eosinophilic esophagitis |
E.1.2 | System Organ Class | 100000004856 |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the long-term safety and tolerability of CC-93538 in subjects with eosinophilic esophagitis (EoE). |
Valutare la sicurezza e la tollerabilità a lungo termine di CC-93538 in soggetti affetti da esofagite eosinofila (EoE). |
|
E.2.2 | Secondary objectives of the trial |
To characterize the immunogenicity profile of CC-93538 following longterm treatment. |
Caratterizzare il profilo di immunogenicità di CC-93538 in seguito al trattamento a lungo termine |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
Other types of substudies Specify title, date and version of each substudy with relative objectives: Endolumenal Functional Lumen Imaging Probe (EndoFLIP TM) Substudy Objective: An optional sub-study will be performed at a subset of clinical sites utilizing an Endolumenal Functional Lumen Imaging Probe (EndoFLIP) to evaluate the effects of CC-93538 on esophageal distensibility.
|
Altre tipologie di sottostudi specificare il titolo, la data e la versione di ogni sottostudio con i relativi obiettivi: Sottostudio sulla sonda endoluminale EndoFLIP (Functional Lumen Imaging Probe) TM Obiettivo: Un sottostudio facoltativo sarà condotto presso un sottogruppo di centri clinici utilizzando una sonda endoluminale EndoFLIP (Functional Lumen Imaging Probe) per valutare gli effetti di CC-93538 sulla distensibilità esofagea.
|
|
E.3 | Principal inclusion criteria |
• Previously participated in prior clinical study CC-93538-EE-001 and either: - completed both the Induction and Maintenance phases; or - completed the Induction Phase, however, did not qualify for the Maintenance Phase, including having a severe EoE flare requiring endoscopic intervention or rescue therapy. • Demonstrated compliance with required investigational product dosing during the prior study. • Did not permanently discontinue investigational product in the prior study and/or did not experience any clinically significant adverse events related to Investigational Product that would preclude further dosing. • Females of childbearing potential must have a negative pregnancy test prior to the first dose of open-label CC-93538 and agree to practice a highly effective method of contraception (as defined in the prior study) until 5 months after the last dose of open-label CC-93538. |
• Pregressa partecipazione al precedente studio clinico CC-93538-EE-001 e: - completamento sia della fase di induzione che di mantenimento; oppure - completamento della fase di induzione, senza però risultare idoneo alla fase di mantenimento, inclusa la presenza di una riacutizzazione grave dell’EoE che ha richiesto un intervento endoscopico o una terapia di soccorso. • Conformità dimostrata alla somministrazione del prodotto sperimentale richiesta durante lo studio precedente. • Nessuna interruzione permanente del prodotto sperimentale nel precedente studio e/o nessuna manifestazione di qualsiasi evento avverso clinicamente significativo correlato al prodotto sperimentale che precluderebbe un’ulteriore somministrazione. • Le donne in età fertile devono presentare un test di gravidanza negativo prima di ricevere la prima dose di CC-93538 in aperto e accettare di adottare un metodo contraccettivo altamente efficace (come definito nel precedente studio) fino a 5 mesi dopo l’ultima dose di CC-93538 in aperto. |
|
E.4 | Principal exclusion criteria |
• Clinical or endoscopic evidence of other diseases or conditions that may affect or confound the histologic, endoscopic, or clinical symptom evaluation for this study. • Active Helicobacter pylori infection or esophageal varices. • Evidence of immunosuppression, or of having received systemic immunosuppressive or immunomodulating drugs within 5 drug half-lives prior to open-label extension study (OLE) Day 1. Use of these agents is prohibited during the study. • Treatment with oral or sublingual immunotherapy within 6 months of OLE Day 1. Use of these agents is prohibited during the study. • Received an investigational product, other than that administered in CC-93538-EE-001, within 5 half-lives prior to OLE Day 1 (includes investigational product received during an interventional trial for COVID19). Those vaccinated with an investigational COVID-19 vaccine during CC-93538-EE-001 are not eligible, unless allowed following a discussion with the Clinical Trial Physician. • Received a live attenuated vaccine within one month prior to OLE Day 1; or anticipates the need for a live attenuated vaccine at any time throughout the course of this study. • Any disease that would affect the conduct of the protocol or interpretation of the study results, or would put a patient at risk by participating in the study (e.g. colitis, celiac disease, Mendelian disorder associated with EoE, severe uncontrolled asthma, infection causing eosinophilia, hypereosinophilic syndrome, or cardiovascular condition, or neurologic or psychiatric illness that could compromise the subject's ability to accurately document symptoms of EoE; newly diagnosed malignancy, lymphoproliferative disease, or clinically significant laboratory abnormality). • Active or ongoing infections including parasitic/helminthic infections, viral hepatitis, tuberculosis, or HIV. • Has had idiopathic anaphylaxis or major immunologic reaction to an immunoglobulin-G containing agent; or any known hypersensitivity to any ingredient in CC-93538. • Females who are pregnant or lactating |
• Evidenza clinica o endoscopica di altre malattie o condizioni che possono influenzare o confondere la valutazione dei sintomi istologici, endoscopici o clinici per questo studio. • Infezione da Helicobacter pylori attiva o varici esofagee. • Evidenza di immunosoppressione o di trattamento con farmaci immunosoppressori sistemici o immunomodulatori entro 5 emivite del farmaco precedentemente al Giorno 1 dello studio di estensione in aperto (Open Label Extension, [OLE]). L’uso di questi agenti è proibito durante lo studio. • Trattamento con immunoterapia per via orale o sublinguale entro 6 mesi dal Giorno OLE 1. L’uso di questi agenti è proibito durante lo studio. • Assunzione di un prodotto sperimentale, diverso da quello somministrato nello studio CC-93538-EE-001, entro 5 emivite precedenti il Giorno OLE 1 (include il prodotto sperimentale ricevuto durante una sperimentazione interventistica per la COVID-19). I vaccinati con un vaccino sperimentale anti-COVID-19 durante CC-93538-EE-001 non sono idonei, a meno che non siano ammessi dopo una discussione con il medico della sperimentazione clinica. • Ricezione di un vaccino vivo attenuato entro un mese prima del Giorno OLE 1 o necessità prevista di ricevere un vaccino vivo attenuato in qualsiasi momento durante tutto il corso di questo studio. • Qualsiasi malattia che renderebbe difficile la conduzione del protocollo o l’interpretazione dei risultati dello studio o che metterebbe il paziente a rischio se partecipasse allo studio (per es., colite, celiachia, disturbo mendeliano associato all’EoE, asma grave non controllata, infezione che causa eosinofilia, sindrome ipereosinofila o malattia cardiovascolare, neurologica o psichiatrica che potrebbe compromettere la capacità del soggetto di documentare accuratamente i sintomi di EoE; neoplasia maligna di nuova diagnosi, malattia linfoproliferativa o anomalia di laboratorio clinicamente significativa). • Infezioni attive o in corso, comprese infezioni parassitarie/elmintiche, epatite virale, tubercolosi o infezione da virus dell’immunodeficienza umana (Human Immunodeficiency Virus, [HIV]). • Pregressa anafilassi idiopatica o reazione immunologica maggiore a un agente contenente immunoglobuline-G; o ipersensibilità nota a qualsiasi ingrediente di CC-93538. • Donne in stato di gravidanza o allattamento |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Safety and tolerability of long-term treatment with CC-93538 evaluated by the incidence, severity, and relationship to CC-93538 of adverse events (AEs), serious adverse events (SAEs), clinical laboratory abnormalities, changes in vital signs, and physical examination abnormalities. |
Sicurezza e tollerabilità del trattamento a lungo termine con CC-93538 valutate mediante l’incidenza, la gravità, e il legame con CC-93538 di eventi avversi (EA), eventi avversi gravi (Serious Adverse Events, [SAE]), anomalie cliniche di laboratorio, variazioni nei segni vitali e anomalie dell’esame obiettivo. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Baseline through Safety Follow-up Visit |
Dal basale alla visita di follow-up di sicurezza |
|
E.5.2 | Secondary end point(s) |
Immunogenicity of CC-93538 assessed through the incidence of antidrug antibodies, including neutralizing antibodies when warranted. |
Immunogenicità di CC-93538 valutata attraverso l’incidenza di anticorpi anti-farmaco, inclusi anticorpi neutralizzanti quando necessario. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Baseline through Safety Follow-up Visit |
Dal basale alla visita di follow-up di sicurezza |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 6 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 64 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Australia |
Canada |
Israel |
Japan |
United States |
Austria |
Belgium |
Germany |
Italy |
Poland |
Portugal |
Spain |
Switzerland |
United Kingdom |
Argentina |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The End of Study is defined as either the date of the last visit of the last subject to complete the post-treatment follow-up, or the date of receipt of the last data point from the last subject that is required for primary, secondary, and/or exploratory analysis, as pre-specified in the protocol, whichever is the later date. |
La fine dello studio è definita come la data dell’ultima visita dell’ultimo soggetto a completamento del follow-up post-trattamento, o come la data di acquisizione degli ultimi dati dell’ultimo soggetto necessari per l’analisi primaria, secondaria e/o esplorativa, a seconda di quale data sia posteriore, come prespecificato nel protocollo. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 4 |
E.8.9.2 | In all countries concerned by the trial months | 4 |
E.8.9.2 | In all countries concerned by the trial days | 0 |